The field of biotherapeutics has been developing quickly- our pipelines have been greatly diversified over the last few years to include different hosts, multi-specific antibodies and antibody-drug conjugates, nanobodies, synthorins relying on an expanded genetic code, gene and cell therapies, enzymes, vaccines and mRNA. In addition, during the COVID-19 pandemic, we have experienced the need to perform process development and to solve very challenging problems in the fast lane. Given the diversity of the pipelines and the need for speed, our collective need for next generation solutions supporting harvest through purification and final formulation has been at the forefront. New chromatog. resins and matrixes with better selectivity and impurity removal, synthetic depth filters with better controlled material attributes, along with solutions offering faster downstream operations, are just a few. Different modes of operation, such as continuous and integrated processing, have also received increased emphasis in order to address the need for speed, for functionally closed operations, using online-monitoring for process operations as well as their ability to control quality attributes and variability in supply requirements. In addition, modeling-aided development, high throughput process development and the utilization of platform knowledge have become more pronounced enablers to meet today's challenges. In this presentation, we will cover these aspects with industry-wide examples and Sanofi-specific case studies.